CVS Stock Forecast 2025-2026
Distance to CVS Price Targets
CVS Price Momentum
10 Quality Stocks Worth Considering Now
Researching CVS (CVS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CVS and similar high-potential opportunities.
Latest CVS Stock Price Targets & Analyst Predictions
Based on our analysis of 40 Wall Street analysts, CVS has a bullish consensus with a median price target of $73.00 (ranging from $48.01 to $86.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $67.20, the median forecast implies a 8.6% upside. This outlook is supported by 19 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Lisa Gill at JP Morgan, projecting a 28.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVS Analyst Ratings
CVS Price Target Range
Latest CVS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $74.00 |
| Feb 18, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $81.00 |
| Feb 13, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $73.00 |
| Feb 13, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $73.00 |
| Feb 13, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $76.00 |
| Feb 13, 2025 | Leerink Partners | Michael Cherny | Outperform | Upgrade | $75.00 |
| Jan 27, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $65.00 |
| Jan 6, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $60.00 |
| Dec 3, 2024 | Deutsche Bank | George Hill | Buy | Upgrade | $66.00 |
| Nov 25, 2024 | TD Cowen | Charles Ryhee | Buy | Maintains | $80.00 |
| Nov 25, 2024 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $64.00 |
| Nov 20, 2024 | Truist Securities | David Macdonald | Buy | Reiterates | $67.00 |
| Nov 18, 2024 | Wells Fargo | Stephen Baxter | Overweight | Upgrade | $66.00 |
| Nov 15, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $58.00 |
| Nov 7, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $71.00 |
| Nov 7, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $62.00 |
| Nov 4, 2024 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $60.00 |
| Oct 24, 2024 | Mizuho | Ann Hynes | Outperform | Maintains | $66.00 |
| Oct 23, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $75.00 |
| Oct 11, 2024 | Truist Securities | David Macdonald | Buy | Maintains | $76.00 |
CVS Health Corporation (CVS) Competitors
The following stocks are similar to CVS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CVS Health Corporation (CVS) Financial Data
CVS Health Corporation has a market capitalization of $84.73B with a P/E ratio of 18.4x. The company generates $370.66B in trailing twelve-month revenue with a 1.2% profit margin.
Revenue growth is +3.6% quarter-over-quarter, while maintaining an operating margin of +2.0% and return on equity of +6.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
CVS Health Corporation (CVS) Business Model
About CVS Health Corporation
Provides comprehensive health services in the U.S.
CVS Health generates revenue through its extensive pharmacy network, retail sales of health products, and its pharmacy benefit management division, Caremark, which administers drug plans. Additionally, owning Aetna allows CVS to integrate insurance services, further diversifying its income streams.
With thousands of retail locations, CVS Health is a key player in the healthcare market, focusing on improving accessibility and convenience for patients. The company's integrated approach enhances its ability to deliver comprehensive healthcare solutions.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
219,000
CEO
Mr. J. David Joyner CEBS
Country
United States
IPO Year
1984
Website
www.cvshealth.comCVS Health Corporation (CVS) Latest News & Analysis
Joe Terranova, Senior Managing Director at Virtus Investment Partners, discussed his recent portfolio moves on CNBC's "Halftime Report."
Joe Terranova's portfolio moves can signal market trends and investment strategies, influencing investor sentiment and stock performance. His insights may affect sector demand and stock prices.
Investors often seek dividend-yielding stocks during market turbulence, favoring companies with strong free cash flows that provide substantial dividends to shareholders.
Dividend-yielding stocks attract investors during market uncertainty, indicating stability and consistent cash flow, which can provide a refuge and potential income amidst volatility.
CVS Health declares quarterly dividend
7 days agoCVS Health's board has approved a quarterly dividend of $0.665 per share for its common stock.
CVS Health’s dividend announcement indicates financial stability and shareholder value, potentially attracting investors seeking income and confidence in the company’s performance.
February investments dropped below $1,000, primarily in BDCs, but annual dividend income rose 5% Y/Y to a record $505, with a goal of increasing monthly dividend income by $100.
Falling investments in BDCs yet rising dividend income indicates strong performance and potential for stable returns, appealing to income-focused investors seeking reliable cash flow.
Investors are advised to monitor Air Canada, Enerflex, AutoNation, Centene, and CVS Health stocks for potential high returns.
Stocks like Air Canada, Enerflex, AutoNation, Centene, and CVS Health may offer strong growth potential, indicating favorable market conditions or company performance that could enhance portfolio returns.
Jeremy Mullin outlines a four-step strategy for 2025 to assist investors in identifying leading stocks and industries during market selloffs, emphasizing disciplined investment approaches.
A structured approach to investing during market downturns can help identify high-potential stocks, enhancing returns and minimizing risks in a volatile environment.
Frequently Asked Questions About CVS Stock
What is CVS Health Corporation's (CVS) stock forecast for 2025?
Based on our analysis of 40 Wall Street analysts, CVS Health Corporation (CVS) has a median price target of $73.00. The highest price target is $86.00 and the lowest is $48.01.
Is CVS stock a good investment in 2025?
According to current analyst ratings, CVS has 19 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $67.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CVS stock?
Wall Street analysts predict CVS stock could reach $73.00 in the next 12 months. This represents a 8.6% increase from the current price of $67.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CVS Health Corporation's business model?
CVS Health generates revenue through its extensive pharmacy network, retail sales of health products, and its pharmacy benefit management division, Caremark, which administers drug plans. Additionally, owning Aetna allows CVS to integrate insurance services, further diversifying its income streams.
What is the highest forecasted price for CVS CVS Health Corporation?
The highest price target for CVS is $86.00 from Lisa Gill at JP Morgan, which represents a 28.0% increase from the current price of $67.20.
What is the lowest forecasted price for CVS CVS Health Corporation?
The lowest price target for CVS is $48.01 from at , which represents a -28.6% decrease from the current price of $67.20.
What is the overall CVS consensus from analysts for CVS Health Corporation?
The overall analyst consensus for CVS is bullish. Out of 40 Wall Street analysts, 19 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $73.00.
How accurate are CVS stock price projections?
Stock price projections, including those for CVS Health Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
